IncreVet, Boston, Massachusetts, USA.
Argenta, New Brunswick, New Jersey, USA.
J Vet Intern Med. 2023 May-Jun;37(3):915-924. doi: 10.1111/jvim.16730. Epub 2023 May 6.
Bexagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. A pilot study has shown that bexagliflozin can decrease dependence on exogenous insulin in cats with diabetes mellitus (DM).
To evaluate the safety and effectiveness of bexagliflozin as a monotherapy for DM in previously untreated cats.
Eighty-four client-owned cats.
Historically controlled prospective open-label clinical trial. Cats were dosed PO with 15 mg bexagliflozin once daily for 56 days, with a 124-day extension to evaluate safety and treatment effect durability. The primary endpoint was the proportion of cats experiencing a decrease in hyperglycemia and improvement in clinical signs of hyperglycemia from baseline on day 56.
Of 84 enrolled cats, 81 were evaluable on day 56, and 68 (84.0%) were treatment successes. Decreases in mean serum glucose, fructosamine, and β-hydroxybutyrate (β-OHB) concentrations were observed, and investigator assessments of cat neurological status, musculature, and hair coat quality improved. Owner evaluations of both cat and owner quality of life were favorable. The fructosamine half-life in diabetic cats was found to be 6.8 days. Commonly observed adverse events included emesis, diarrhea, anorexia, lethargy, and dehydration. Eight cats experienced serious adverse events, 3 of which led to death or euthanasia. The most important adverse event was euglycemic diabetic ketoacidosis, diagnosed in 3 cats and presumed present in a fourth.
Bexagliflozin decreased hyperglycemia and observed clinical signs in cats newly diagnosed with DM. As a once-daily PO medication, bexagliflozin may simplify management of DM in cats.
贝格列净是一种钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂。一项初步研究表明，贝格列净可降低糖尿病（DM）猫对外源胰岛素的依赖。
评估贝格列净单药治疗未经治疗的 DM 猫的安全性和有效性。
84 只患宠猫。
历史对照前瞻性开放标签临床试验。猫每天 PO 口服 15mg 贝格列净，连续 56 天，然后延长至 124 天，以评估安全性和治疗效果的持久性。主要终点是第 56 天血糖升高缓解且高血糖临床症状改善的猫比例。
在 84 只入组猫中，81 只在第 56 天可评估，68 只（84.0%）为治疗成功。观察到血清葡萄糖、果糖胺和β-羟丁酸（β-OHB）浓度降低，猫的神经状态、肌肉和被毛质量改善，研究者评估得到改善。猫和主人的生活质量都得到了主人的好评。还发现糖尿病猫的果糖胺半衰期为 6.8 天。常见的不良反应包括呕吐、腹泻、厌食、嗜睡和脱水。8 只猫发生严重不良事件，其中 3 只导致死亡或安乐死。最重要的不良事件是血糖正常的糖尿病酮症酸中毒，3 只猫被诊断出，推测还有 1 只猫也存在这种情况。
贝格列净可降低新诊断为 DM 的猫的高血糖和观察到的临床症状。作为一种每日一次的 PO 药物，贝格列净可能简化 DM 猫的管理。
